In this free webinar, gain insights into the most recent assays and disease models for T1 and T2 diabetes that have been developed using the fully functional and standardized EndoC-βH5 human beta cells. Join the featured speakers as they discuss existing models and solutions for biomedical research and drug development in diabetes based on the newly developed EndoC-βH5 primary-like human beta cells, which combine robust glucose-stimulated insulin secretion and GLP-1/GIP receptor activities and modeling of human T1 & T2 diabetes.
TORONTO, Oct. 18, 2023 /PRNewswire-PRWeb/ -- In this webinar, the featured speakers will talk about the contribution and convenience of in vitro human cell assays using primary-like human beta cells and associated tools for diabetes research. Optimized physiological, functional and pharmacologically predictive in vitro models have the potential to accelerate drug discovery and development, prompting safer and more efficient drugs.
EndoC-βH5 cells are a recently established human beta-cell model. These cells represent a unique storable and ready-to-use tool with highly robust and reproducible features. This model, when exposed to different stimuli is thus relevant for the study of beta-cell function, screening and validation of new drugs and development of disease models.
As an example, glucose stimulation of the EndoC-βH5 cells will result in the secretion of insulin in a dynamic manner and this secretion can be enhanced by GLP-1 (glucagon‐like peptide) and GIP (glucose‐dependent insulinotropic polypeptide) analogs. In this way, EndoC-βH5 based disease models for T1 and T2 diabetes, allow lead identification and optimization in drug development without compromising highly reproducible results and providing an accurate understanding of beta-cell function. Thus, showing that EndoC-βH5 cells can grant relevant early drug discovery through beta-cell function characterization and target identification and validation approaches.
Join the featured speakers as they discuss existing models and solutions for biomedical research and drug development in diabetes based on the newly developed EndoC-βH5 primary-like human beta cells, which combine robust glucose-stimulated insulin secretion and GLP-1/GIP receptor activities and modeling of human T1 & T2 diabetes.
Join Bruno Blanchi, PhD, Chief Scientific Officer, Human Cell Design; and Miguel Sáinz Jaspeado, PhD, Scientific Affairs Manager, Mercodia, for the live webinar on Thursday, November 02, 2023, at 9:30am EDT (2:30pm CET/EU-Central).
For more information, or to register for this event, visit EndoC-βH5 Human Beta Cells in T1 and T2 Diabetes Models.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article